We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 24, 2020

Cisplatin and 5-FU ± EGFR Inhibition for Nonresectable, Advanced, or Metastatic Esophageal Squamous Cell Cancer

Annals of Oncology

 

Additional Info

Annals of Oncology
Cisplatin and 5-Fluorouracil With or Without Epidermal Growth Factor Receptor Inhibition Panitumumab for Patients With Non-Resectable, Advanced or Metastatic Oesophageal Squamous Cell Cancer: A Prospective, Open-Label, Randomised Phase III AIO/EORTC Trial (POWER)
Ann. Oncol 2020 Jan 06;[EPub Ahead of Print], M Moehler, A Maderer, PC Thuss-Patience, et al

Further Reading